ABSTRACT
This article explores the relationship between trade policy and access to drugs, using the arv drugs as an example. It begins by noting the moral problem of inequality in access to drugs. It goes on to explore the political problem in terms of the discrepancy between what is legal/permissible under wto rules, and what is permissible/desirable under the terms of US trade policy. Finally, it explores the problem of credibility for global health governance and the global market system in terms of access to drugs.
